Clinical Research Directory

Inclusion Criteria: In order to be eligible for this study, a participant must meet all of the following criteria: 1. Adults ≥ 18 years old diagnosed with PAH. 2. Treatment with sotatercept for ≥6 months. 3. Background therapy with ≥2 PAH vasodilator therapies, one of which is a parenteral prostacyclin or selexipag. 4. At low or intermediate-low risk, defined using the 2022 ESC/ERS guidelines 4-strata risk assessment tool (Table 1). 5. RHC at screening or historical within 8 weeks of screening, and after at least 6 months of sotatercept treatment, demonstrating a mPAP ≤40 mmHg and PVR ≤5 WU 6. The ability to adhere to the study visit schedule and to comprehend and comply with all protocol requirements. 7. Ability to provide informed consent. Exclusion Criteria: A potential participant who meets any of the following criteria will be excluded from participation in this study: 1. Known intolerance to sotatercept 2. A RHC at screening or historical within 8 weeks of screening and after ≥6 months of sotatercept treatment demonstrating mPAP \> 40 mmHg or PVR \> 5 WU. 3. Hospitalization for worsening PAH or right heart failure within the 3 months prior to screening. 4. Active listing for lung or heart/lung transplantation. 5. Metastatic cancer or any other condition with a life expectancy \< 6 months, 6. Female patients who are pregnant or who are of childbearing age and are unwilling to use contraception during the study. 7. History of ≥ 3 interruptions or missed doses of sotatercept for any reason within the previous 6 months prior to screening. 8. Patients who received any investigational medication within 1 month prior to screening (unless known to be placebo) or who are scheduled to receive another investigational drug during the course of this study.